Serine Palmitoyltransferase (SPTLC2) (C-term) Rabbit Polyclonal Antibody

CAT#: AP12257PU-N

Serine Palmitoyltransferase (SPTLC2) (C-term) rabbit polyclonal antibody, Purified



Need it in bulk or conjugated?
Get a free quote

CNY 6,160.00


货期*
5周

规格
    • 400 ul

Cited in 1 publication.

Product images

Specifications

Product Data
Applications WB
Recommend Dilution Western Blot: ~1/1000.
Reactivity Human, Mouse
Host Rabbit
Clonality Polyclonal
Immunogen KLH conjugated synthetic peptide between 531-562 amino acids from the C-terminal region of human Serine Palmitoyltransferase (SPTLC2).
Specificity This antibody is specific to SPTLC2 (C-term).
Formulation PBS with 0.09% (W/V) Sodium Azide as preservative.
State: Purified
State: Liquid purified Ig fraction.
Concentration lot specific
Purification Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS
Conjugation Unconjugated
Storage Condition Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.
Avoid repeated freezing and thawing.
Gene Name serine palmitoyltransferase long chain base subunit 2
Background Serine palmitoyltransferase (SPT) is the key enzyme in sphingolipid biosynthesis. It catalyzes the pyridoxal-5-prime-phosphate-dependent condensation of L-serine and palmitoyl-CoA to 3-oxosphinganine. 
The heterodimer formed with LCB1/SPTLC1 constitutes the catalytic core. The composition of the serine palmitoyltransferase (SPT) complex determines the substrate preference. The SPTLC1-SPTLC2-SPTSSA complex shows a strong preference for C16-CoA substrate, while the SPTLC1-SPTLC2-SPTSSB complex displays a preference for C18-CoA substrate.
Synonyms Serine palmitoyltransferase 2, SPT 2, SPT2, LCB 2, LCB2, LCB2a, KIAA0526
Note Predicted Molecular weight: 62924 Da
Reference Data
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Citations (1)

Customer Reviews 
Loading...